validating biomarkers regulatory issues aside pharmaceutical industry strong profit motive avoiding personalizing medicine reluctance come desire not limit market test identifying will not respond drug means fewer patients buy companies worried perceive fear loss blockbuster model drug development reed notes path developing new drugs clear personalized medicine equally important role play drugs market companies focused discovering new pharmacogenomic medicines academic researchers begun apply genomics understood cytochrome p450 cyp450 group genes encode family liver enzymes enzymes metabolize medicines market blood thinner warfarin codeine antidepressants mutations genes patients metabolize drugs slowly quickly normal means drug standard dose small effective large causing effects